Widespread Use of Measurable Residual Disease in Acute Myeloid Leukemia Practice

被引：0
作者：
Epstein-Peterson, Zachary D.
Devlin, Sean M.
Stein, Eytan M.
Estey, Elihu H.
Tallman, Martin S.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5103
引用
收藏
页数：2
相关论文
共 50 条
[21]   Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia [J].
Gaut, Daria ;
Oliai, Caspian ;
Boiarsky, Jonathan ;
Zhang, Shiliang ;
Salhotra, Amandeep ;
Azenkot, Tali ;
Kennedy, Vanessa E. ;
Khanna, Vishesh ;
Olmedo Gutierrez, Karla ;
Shukla, Navika ;
Moskoff, Benjamin ;
Park, Gabriel ;
Afkhami, Michelle ;
Patel, Anand ;
Jeyakumar, Deepa ;
Mannis, Gabriel ;
Logan, Aaron C. ;
Jonas, Brian A. ;
Schiller, Gary .
LEUKEMIA & LYMPHOMA, 2024, 65 (01) :69-77
[22]   Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia [J].
Palmieri, Raffaele ;
Buccisano, Francesco ;
Maurillo, Luca ;
Del Principe, Maria, I ;
Paterno, Giovangiacinto ;
Venditti, Adriano ;
Martinelli, Giovanni ;
Cerchione, Claudio .
MINERVA MEDICA, 2020, 111 (05) :386-394
[23]   Measurable residual disease in multiple myeloma and in acute myeloid leukemia, an evolving topic [J].
Castelli, Germana ;
Pelosi, Elvira ;
Testa, Ugo .
ANNALI DELL ISTITUTO SUPERIORE DI SANITA, 2021, 57 (04) :300-313
[24]   Reproducibility of measurable residual disease detection by flow cytometry in acute myeloid leukemia [J].
Roehnert, M. A. ;
Kramer, M. ;
Schadt, J. ;
Ensel, P. ;
Thiede, C. ;
Krause, S. ;
Buecklein, V ;
Hoffmann, J. ;
Jaramillo, S. ;
Schlenk, R. ;
Roellig, C. ;
Bornhaeuser, M. ;
McCarthy, N. ;
Freeman, S. ;
Oelschlaegel, U. ;
von Bonin, M. .
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) :278-278
[25]   Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia [J].
Percival, Mary-Elizabeth M. ;
Estey, Elihu H. .
CANCER, 2019, 125 (18) :3121-3130
[26]   Detection and management of acute myeloid leukemia measurable residual disease: is it standard of care? [J].
Paterno, Giovangiacinto ;
Del Principe, Maria Ilaria ;
Venditti, Adriano .
CURRENT OPINION IN HEMATOLOGY, 2020, 27 (02) :81-87
[27]   Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia [J].
Wong, Zoe C. ;
Dillon, Laura W. ;
Hourigan, Christopher S. .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2023, 36 (02)
[28]   Detection methods and prognosis implications of measurable residual disease in acute myeloid leukemia [J].
Zhao, Zihan ;
Lan, Jianping .
ANNALS OF HEMATOLOGY, 2024, 103 (12) :4869-4881
[29]   Tracking Measurable Residual Disease in Acute Myeloid Leukemia with Error Corrected Sequencing [J].
D'Angelo, J. ;
Huang, Y. ;
Kebede, Y. ;
Miick, S. ;
Salva, N. ;
Troung, C. ;
Turner, S. .
JOURNAL OF MOLECULAR DIAGNOSTICS, 2022, 24 (10) :S38-S38
[30]   Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations [J].
Walter, Roland B. ;
Ofran, Yishai ;
Wierzbowska, Agnieszka ;
Ravandi, Farhad ;
Hourigan, Christopher S. ;
Ngai, Lok Lam ;
Venditti, Adriano ;
Buccisano, Francesco ;
Ossenkoppele, Gert J. ;
Roboz, Gail J. .
LEUKEMIA, 2021, 35 (06) :1529-1538
12345